yahoo_financeOriginal article
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Trial StartNV-387Positive
AI Analysis
Summary
NanoViricides has announced the start of patient enrollment and dosing in a clinical trial for NV-387, an oral drug candidate for treating Ebola, with enrollment beginning around September 23rd.
Clinical Trial Data
Importance:5/10
Sentiment:
0.50
clinical_trialoral_drugebolatrial_enrollment
Related Companies
Read the original article
Published by yahoo_finance on September 28, 2026 12:45 PM